Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Kennedy, Jae
Tien, Yu Yu
Cohen, Lawrence J.
Sclar, David Alexander
Liu, Darren
Blodgett, Elizabeth G.
and
Engle, Josh
2009.
The association between class of antipsychotic and rates of hospitalization: Results of a retrospective analysis of data from the 2005 medicare current beneficiary survey.
Clinical Therapeutics,
Vol. 31,
Issue. 12,
p.
2931.
Centorrino, Franca
Ventriglio, Antonio
Vincenti, Alessio
Talamo, Alessandra
and
Baldessarini, Ross J.
2010.
Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004.
Human Psychopharmacology: Clinical and Experimental,
Vol. 25,
Issue. 2,
p.
179.
Mattai, Anand K
Hill, Julia L
and
Lenroot, Rhoshel K
2010.
Treatment of early-onset schizophrenia.
Current Opinion in Psychiatry,
Vol. 23,
Issue. 4,
p.
304.
Kane, John M.
and
Correll, Christoph U.
2010.
Pharmacologic treatment of schizophrenia.
Dialogues in Clinical Neuroscience,
Vol. 12,
Issue. 3,
p.
345.
Semenova, Svetlana
and
Markou, Athina
2010.
The α2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats.
European Neuropsychopharmacology,
Vol. 20,
Issue. 10,
p.
731.
2010.
The Use and Misuse of Psychiatric Drugs.
p.
165.
Terry, Alvin V.
Gearhart, Debra A.
Pillai, Anilkumar
Zhang, Guodong
and
Bartlett, Michael G.
2010.
Chronic antipsychotic treatment: protracted decreases in phospho-TrkA levels in the rat hippocampus.
The International Journal of Neuropsychopharmacology,
Vol. 13,
Issue. 06,
p.
799.
Beninger, Richard J.
Baker, Tyson W.
Florczynski, Matthew M.
and
Banasikowski, Tomek J.
2010.
Regional Differences in the Action of Antipsychotic Drugs: Implications for Cognitive Effects in Schizophrenic Patients.
Neurotoxicity Research,
Vol. 18,
Issue. 3-4,
p.
229.
Leucht, Stephan
Correll, Christoph U.
and
Kane, John M.
2010.
Schizophrenia.
p.
540.
Kim, Sung‐Wan
Yoo, Joon‐An
Lee, Sam‐Yeon
Kim, Seon‐Young
Bae, Kyung‐Yeol
Yang, Su‐Jin
Kim, Jae‐Min
Shin, Il‐Seon
and
Yoon, Jin‐Sang
2010.
Risperidone versus olanzapine for the treatment of delirium.
Human Psychopharmacology: Clinical and Experimental,
Vol. 25,
Issue. 4,
p.
298.
Citrome, L.
2010.
Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic.
International Journal of Clinical Practice,
Vol. 64,
Issue. 6,
p.
707.
Rummel-Kluge, Christine
Komossa, Katja
Schwarz, Sandra
Hunger, Heike
Schmid, Franziska
Lobos, Claudia Asenjo
Kissling, Werner
Davis, John M.
and
Leucht, Stefan
2010.
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis.
Schizophrenia Research,
Vol. 123,
Issue. 2-3,
p.
225.
Gaebel, Wolfgang
Riesbeck, Mathias
and
Wobrock, Thomas
2011.
Schizophrenia guidelines across the world: A selective review and comparison.
International Review of Psychiatry,
Vol. 23,
Issue. 4,
p.
379.
Werneck, Ana Paula
Hallak, Jaime Cecilio
Nakano, Eduardo
and
Elkis, Helio
2011.
Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine.
Psychiatry Research,
Vol. 188,
Issue. 3,
p.
315.
Leucht, S.
Heres, S.
and
Davis, J. M.
2011.
Überlegungen zur Wirksamkeit von Psychopharmaka.
Der Nervenarzt,
Vol. 82,
Issue. 11,
p.
1425.
Hasan, Alkomiet
Wobrock, Thomas
Reich-Erkelenz, Daniela
and
Falkai, Peter
2011.
Treatment of first-episode schizophrenia: pharmacological and neurobiological aspects.
Drug Discovery Today: Therapeutic Strategies,
Vol. 8,
Issue. 1-2,
p.
31.
Kendall, Tim
2011.
The rise and fall of the atypical antipsychotics.
British Journal of Psychiatry,
Vol. 199,
Issue. 4,
p.
266.
Bernardo, Miquel
Vieta, Eduard
Saiz Ruiz, Jerónimo
Rico-Villademoros, Fernando
Álamo, Cecilio
and
Bobes, Julio
2011.
Recomendaciones para el cambio de antipsicóticos. Posicionamiento de la Sociedad Española de Psiquiatría y Sociedad Española de Psiquiatría Biológica.
Revista de Psiquiatría y Salud Mental,
Vol. 4,
Issue. 3,
p.
150.
Ye, Wenyu
Nakahara, Naohiro
Takahashi, Michihiro
and
Ascher-Svanum, Haya
2011.
Characteristics of Outpatients Initiated on Olanzapine versus Risperidone in the Treatment of Schizophrenia in Japan: A Healthcare Database Analysis.
Clinical Neuropsychopharmacology and Therapeutics,
Vol. 2,
Issue. 0,
p.
1.
Fraguas, David
Correll, Christoph U.
Merchán-Naranjo, Jessica
Rapado-Castro, Marta
Parellada, Mara
Moreno, Carmen
and
Arango, Celso
2011.
Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons.
European Neuropsychopharmacology,
Vol. 21,
Issue. 8,
p.
621.